Publicaciones en colaboración con investigadoras/es de Instituto de Investigación Sanitaria Biobizkaia (40)

2024

  1. PEACE V-Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): Acute Toxicity of a Randomized Phase 2 Trial

    European urology oncology, Vol. 7, Núm. 3, pp. 462-468

  2. Prospective study of HDR brachytherapy (BT), external beam radiotherapy (EBRT) and androgen deprivation therapy (ADT): 10-years experience of an MRI-guided approach

    Radiotherapy and Oncology, Vol. 190

2023

  1. A multidisciplinary consensus statement on the optimal pharmacological treatment for metastatic hormone-sensitive prostate cancer

    Actas Urologicas Espanolas, Vol. 47, Núm. 2, pp. 111-126

  2. Abiraterone in low-volume metastatic hormone-sensitive prostate cancer. Authors’ reply

    Actas Urologicas Espanolas

  3. ESTRO ACROP consensus recommendation on the target volume definition for radiation therapy of macroscopic prostate cancer recurrences after radical prostatectomy

    Clinical and Translational Radiation Oncology, Vol. 43

  4. ESTRO ACROP guideline on prostate bed delineation for postoperative radiotherapy in prostate cancer

    Clinical and Translational Radiation Oncology, Vol. 41

  5. Long-term outcomes of ultra-hypofractionated 2 fractions single day HDR brachytherapy in localized prostate cancer

    Radiotherapy and Oncology, Vol. 186

2022

  1. Oligorecurrent nodal prostate cancer: Radiotherapy quality assurance of the randomized PEACE V-STORM phase II trial

    Radiotherapy and Oncology, Vol. 172, pp. 1-9

  2. Phase II Study of ENZAlutamide Combined With Hypofractionated Radiation Therapy (ENZART) for Localized Intermediate Risk Prostate Cancer

    Frontiers in Oncology, Vol. 12

  3. Quality of life improvement in patients with bone metastases undergoing palliative radiotherapy

    Reports of Practical Oncology and Radiotherapy, Vol. 27, Núm. 3, pp. 428-439

  4. Recommendations for radiation therapy in oligometastatic prostate cancer: An ESTRO-ACROP Delphi consensus

    Radiotherapy and Oncology, Vol. 176, pp. 199-207

  5. Should brachytherapy be added to external beam radiotherapy for prostate cancer?

    The Lancet Oncology, Vol. 23, Núm. 1, pp. 23-25

2021

  1. A retrospective study on the potential of 99mTc-HDP imaging before therapy for individualizing treatments with 223Ra-Cl2 for metastatic castration resistant prostate cancer

    Medical Physics, Vol. 48, Núm. 3, pp. 1395-1403

  2. Adjuvant versus early salvage radiotherapy for prostate cancer patients: Time to move on

    Urologic Oncology: Seminars and Original Investigations, Vol. 39, Núm. 6, pp. 351-356

  3. Salvage brachytherapy for locally recurrent prostate cancer after single-fraction 19 Gy high-dose-rate brachytherapy: Toxicity, prostatespecific antigen kinetics, and cancer control

    Journal of Contemporary Brachytherapy, Vol. 13, Núm. 1, pp. 12-17

  4. Salvage local treatment for localized radio-recurrent prostate cancer: A narrative review and future perspectives

    Future Oncology, Vol. 17, Núm. 31, pp. 4207-4219

  5. The Multicenter, Randomized, Phase 2 PEACE V-STORM Trial: Defining the Best Salvage Treatment for Oligorecurrent Nodal Prostate Cancer Metastases

    European Urology Focus

2020

  1. Clinical applications of molecular biomarkers in prostate cancer

    Cancers, Vol. 12, Núm. 6, pp. 1-25

  2. MRI detected extaprostatic extension (EPE) in prostate cancer: Do all T3a patients have the same outcomes?

    Clinical and Translational Radiation Oncology, Vol. 24, pp. 135-139

  3. Microdosimetry-based determination of tumour control probability curves for treatments with 225Ac-PSMA of metastatic castration resistant prostate cancer

    Physics in Medicine and Biology, Vol. 65, Núm. 23